Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CytomX Therapeutics (CTMX) EBIT: 2013-2024

Historic EBIT for CytomX Therapeutics (CTMX) over the last 12 years, with Dec 2024 value amounting to $25.0 million.

  • CytomX Therapeutics' EBIT fell 483.56% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year increase of 246.44%. This contributed to the annual value of $25.0 million for FY2024, which is 485.49% up from last year.
  • As of FY2024, CytomX Therapeutics' EBIT stood at $25.0 million, which was up 485.49% from -$6.5 million recorded in FY2023.
  • In the past 5 years, CytomX Therapeutics' EBIT registered a high of $25.0 million during FY2024, and its lowest value of -$116.0 million during FY2021.
  • Over the past 3 years, CytomX Therapeutics' median EBIT value was -$6.5 million (recorded in 2023), while the average stood at -$27.6 million.
  • In the last 5 years, CytomX Therapeutics' EBIT slumped by 44.08% in 2021 and then spiked by 485.49% in 2024.
  • Yearly analysis of 5 years shows CytomX Therapeutics' EBIT stood at -$80.5 million in 2020, then slumped by 44.08% to -$116.0 million in 2021, then increased by 12.67% to -$101.3 million in 2022, then soared by 93.60% to -$6.5 million in 2023, then surged by 485.49% to $25.0 million in 2024.